Claims for Patent: 6,541,450

Summary for Patent: 6,541,450

Title:	Parathyroid hormone analogues for the treatment of osteoporosis
Abstract:	This invention describes analogues of human parathyroid hormone which have increased activities in bone restoration, and increased bioavailability. The peptides described are derivatives of hPTH-(1-31) which are cyclized for example, by formation of lactams between either Glu.sup.22 and Lys.sup.26 or Lys.sup.26 and Asp.sup.30. In addition, the natural Lys.sup.27 may be substituted by either a Leu or other hydrophobic residues, such as Ile, norleucine, Met, Val, Ala, Trp, or Phe. Typically, these analogues have enhanced abilities to stimulate adenylyl cyclase in rat osteosarcoma cells, and show increased activities in bone restoration, using the ovariectomized rat model. The analogues also show enhanced activities and bioavailabilities, as demonstrated by their hypotensive effects in the rat. An assay which correlates hypotensive activity with osteogenic activity is also described.
Inventor(s):	Barbier; Jean-Rene (Gatineau, CA), Morley; Paul (Ottawa, CA), Neugebauer; Witold (Ottawa, CA), Whitfield; James F. (Ottawa, CA), Willick; Gordon E. (Orleans, CA)
Assignee:	National Research Council of Canada (Ontario, CA)
Application Number:	09/536,785
Patent Claims:	1. A human parathyroid hormone hPTH-(1-31) analogue in which position 27 is Lys or has been substituted by Ala, Tyr or Gln, and which has been cyclized between Glu.sup.22 and Lys.sup.26 to form a lactam. 2. An analogue according to claim 1, having either a C-terminal amide ending or a C-terminal carboxyl ending. 3. A composition for administration to a warm-blooded animal in need thereof, comprising a human parathyroid hormone (hPTH)-(1-31) analogue according to claim 1, in association with a pharmaceutically acceptable carrier or excipient. 4. A method of treating a warm-blooded animal in need of such treatment, comprising administering to such warm-blooded animal, a therapeutically effective amount of a human parathyroid hormone (hPTH)-(1-31) analogue according to claim 1. 5. A human parathyroid hormone hPTH analogue and pharmaceutically acceptable salts thereof, having the amino acid sequence R--NH-R1-Val-Ser-Glu-Ile-Gln-Leu-R2-His-Asn-Leu-Gly-Lys-R3-R4-R5-R6-R7-Glu- Arg-Val-R8--Trp-Leu-R9-R10-R11-Leu-R12-Asp-Y (SEQ ID NO: 23) wherein, R=hydrogen, R1=Ser, R2=Met, R3=His or Lys, R4=Leu or Lys, R5=Asn or Lys, R6=Ser or Lys, R7=Met, R8=Glu or Lys, R9=Arg, R10=Glu or Lys provided that R8 and R10 are not both Glu and are not both Lys, R11=Lys or Leu, R12=Gln, X=OH, or NH.sub.2, and Y=Val-X (SEQ ID NO: 36), Val-His-X (SEQ ID NO: 37), Val-His-Asn-X (SEQ ID NO: 38) or Val-His-Asn-Phe-X (SEQ ID NO: 24) cyclized in the form of a lactam between amino acid pair 22 and 26, excluding when R=H, R1=Ser, R2=Met, R3=His, R4=Leu, R5=Asn, R6=Ser, R7=Met, R8=Glu, R9=Arg, R10=Lys, R11=Leu, R12=Gln, X=OH or NH.sub.2, and Y=Val-X together. 6. An analogue according to claim 5, wherein the lactam is a Glu22-Lys26 lactam. 7. An analogue according to claim 5, wherein R is H and X is NH.sub.2. 8. An analogue according to claim 7, wherein R2 is Met, R7 is Met, R8 is Glu, and R10 is Lys. 9. An analogue according to claim 8, wherein Y=Val-X. 10. An analogue according to claim 8, wherein Y=Val-His-Asn-Phe-X (SEQ ID NO:24). 11. An analogue having the SEQ ID NO: 9. 12. An analogue having the SEQ ID NO: 10. 13. An analogue having the SEQ ID NO: 11. 14. An analogue having the SEQ ID NO: 13. 15. An analogue having the SEQ ID NO: 14. 16. An analogue having the SEQ ID NO: 16. 17. An analogue having the SEQ ID NO: 18. 18. An analogue having the SEQ ID NO: 19.

Details for Patent 6,541,450

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2014-06-20